Rodman & Renshaw initiated coverage of Adial Pharmaceuticals (ADIL) with a Buy rating and $8 price target The firm believes Adial has the potential to outperform over the next 12 months, saying its ...

Confirmed relative bioavailability to the reference standard, dose proportional increases in pharmacokinetic exposure, and no food effectMarks ...

Thursday, Adial Pharmaceuticals Inc (NASDAQ:ADIL) said it has completed a pharmacokinetics (PK) study of AD04 for Alcohol Use ...

SAIHEAT Limited (f/k/a SAI.TECH Global Corporation) ("SAIHEAT” or the "Company”) (NASDAQ: SAIH, SAITW) is pleased to unveil the SAIHEAT BASE PLAN 2029, an ambitious initiative delivering integrated ...

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL – Get Free Report) saw a large growth in short interest during the month of October. As of October 31st, there was short interest totalling 78,900 shares, a ...

Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for ...

Emergent BioSolutions appointed Dr. Simon Lowry as chief medical officer and head of research and development. CureVac named ...

Last year, the council approved stipends worth another $39,996 a year. Started career in pharmaceuticals, recruited into DuPont joint venture. Built, staffed, operated plant successfully.

GLEN ALLEN, Va., Nov. 05, 2024 (GLOBE NEWSWIRE) -- . (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage ...

GLEN ALLEN, Va., Oct. 23, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and ...